Q1 2023 EPS Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA) Lowered by Zacks Research

Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Rating) – Equities researchers at Zacks Research decreased their Q1 2023 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a report released on Tuesday, September 20th. Zacks Research analyst K. Shah now anticipates that the company will earn $0.53 per share for the quarter, down from their previous estimate of $0.54. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.45 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q3 2023 earnings at $0.56 EPS, Q4 2023 earnings at $0.66 EPS, FY2023 earnings at $2.32 EPS and Q2 2024 earnings at $0.61 EPS.

Several other equities research analysts also recently weighed in on the company. StockNews.com raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Friday, June 17th. Bank of America raised Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and increased their price target for the stock from $10.00 to $13.00 in a report on Friday, August 5th. UBS Group started coverage on Teva Pharmaceutical Industries in a report on Monday, June 13th. They set a “neutral” rating and a $10.00 price target for the company. Finally, The Goldman Sachs Group increased their price target on Teva Pharmaceutical Industries from $9.00 to $10.00 and gave the stock a “neutral” rating in a report on Tuesday, August 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $10.67.

Teva Pharmaceutical Industries Stock Down 2.9 %

TEVA stock opened at $8.42 on Wednesday. Teva Pharmaceutical Industries has a twelve month low of $6.78 and a twelve month high of $11.34. The business has a 50 day simple moving average of $9.18 and a 200-day simple moving average of $8.72. The company has a debt-to-equity ratio of 2.07, a current ratio of 1.11 and a quick ratio of 0.74.

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.09. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.82 billion. Teva Pharmaceutical Industries had a positive return on equity of 25.68% and a negative net margin of 6.83%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TEVA. Capital Research Global Investors increased its position in shares of Teva Pharmaceutical Industries by 11.3% in the fourth quarter. Capital Research Global Investors now owns 132,350,750 shares of the company’s stock valued at $1,060,109,000 after buying an additional 13,474,099 shares in the last quarter. Woodline Partners LP purchased a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at $15,342,000. Arrowstreet Capital Limited Partnership increased its position in Teva Pharmaceutical Industries by 953.6% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,028,487 shares of the company’s stock worth $19,047,000 after purchasing an additional 1,835,952 shares in the last quarter. Bank of Montreal Can increased its position in Teva Pharmaceutical Industries by 88.4% during the 1st quarter. Bank of Montreal Can now owns 3,811,347 shares of the company’s stock worth $35,788,000 after purchasing an additional 1,787,830 shares in the last quarter. Finally, Allianz Asset Management GmbH purchased a new stake in Teva Pharmaceutical Industries during the 1st quarter worth about $15,844,000. Hedge funds and other institutional investors own 46.22% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CFO Eliyahu Sharon Kalif sold 55,500 shares of the firm’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $10.07, for a total value of $558,885.00. Following the completion of the sale, the chief financial officer now owns 9,376 shares of the company’s stock, valued at $94,416.32. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Teva Pharmaceutical Industries news, CFO Eliyahu Sharon Kalif sold 55,500 shares of the firm’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $10.07, for a total value of $558,885.00. Following the completion of the sale, the chief financial officer now owns 9,376 shares of the company’s stock, valued at $94,416.32. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP David Matthew Stark sold 58,163 shares of the firm’s stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $9.04, for a total value of $525,793.52. Following the completion of the sale, the vice president now directly owns 2,974 shares of the company’s stock, valued at approximately $26,884.96. The disclosure for this sale can be found here. 0.82% of the stock is owned by corporate insiders.

About Teva Pharmaceutical Industries

(Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Featured Stories

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.